ZVRA vs DMAC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ZVRA Captures Institutional Edge (2โ2 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zevra Therapeutics, Inc. Common Stock (ZVRA) driven by superior Valuation, Growth & Margin while DMAC counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ZVRA trades at 9.3x Forward P/E with 31.5% operating margin (+44.9% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ZVRA sits in BREAKDOWN (14th %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ZVRA Revenue | DMAC Revenue | ZVRA Op. Margin | DMAC Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -1352.2% | DMAC |
| FY2019 | $10M | N/A | -158.4% | N/A | ZVRA |
| FY2020 | $10M | N/A | -42.2% | N/A | ZVRA |
| FY2021 | $30M | N/A | 27.0% | N/A | ZVRA |
| FY2022 | $10M | N/A | -418.9% | N/A | ZVRA |
| FY2023 | $30M | N/A | -180.6% | N/A | ZVRA |
| FY2024 | $20M | N/A | -368.5% | N/A | ZVRA |
| FY2025 | $110M | N/A | -59.1% | N/A | ZVRA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ZVRA | DMAC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $664.1M | $503.1M | Larger Scale | ZVRA |
| Trailing P/E Ratio Valuation | 9.7x | N/M | Lower Multiple | ZVRA |
| Forward P/E Ratio Valuation | 9.3x | N/M | Lower Multiple | ZVRA |
| Revenue Growth (YoY) Growth | +44.9% | +0.0% | Higher Growth | ZVRA |
| Operating Margin (TTM) Profitability | 31.5% | 0.0% | Higher Margin | ZVRA |
| Net Profit Margin Profitability | 52.8% | 0.0% | Higher Margin | ZVRA |
| Return on Equity (ROE) Capital Efficiency | 41.9% | -114.6% | Higher ROE | ZVRA |
| 52-Week Range Position Momentum | 18% ($8โ$15) | 55% ($5โ$11) | Stronger Trend | DMAC |
| Beta / 30D Volatility Risk Regime | 1.18ฮฒ ยท 95% Vol | 1.74ฮฒ ยท 98% Vol | Lower Realized Risk | ZVRA |
| Unified Institutional Score Composite Signal | 49.4 / 100 (HOLD) | 46.3 / 100 (HOLD) | Higher Composite | ZVRA |